Business
Press Release: Annual General Meeting of April 29, 2026 - Belén Garijo appointed as Director and Chief Executive Officer of Sanofi
Annual General Meeting of April 29, 2026 Belén Garijo appointed as Director and Chief Executive Officer of Sanofi Paris, April 29, 2026. Sanofi's Mixed General Meeting of Shareholders convened on April 29, 2026, under the chairmanship of Frédéric Oudéa. All resolutions were approved with a high level of shareholder support, in particular the appointment of Belén Garijo as a board member. In line with the Board’s decision of February 11, Belén Garijo will assume her duties as Chief Executive Offi
About this update from Sanofi Sa
[{"type":"image","alt":"Sanofi Winthrop Industrie","displaySize":"","headline":null,"caption":"Sanofi Winthrop Industrie","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":84,"url":"https://media.zenfs.com/en/globenewswire.com/c45c40f5ed741dd9c0f5c2f75b8fc137"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/739gYr0oCQk4PhnczLgzIQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExOA--/https://media.zenfs.com/en/globenewswire.com/c45c40f5ed741dd9c0f5c2f75b8fc137","width":300,"height":84}},"lazy":false},{"type":"text","content":"Annual General Meeting of April 29, 2026","length":40,"tagName":"p"},{"type":"text","content":"Belén Garijo appointed as Director and Chief Executive Officer of Sanofi","length":72,"tagName":"p"},{"type":"text","content":"Paris, April 29, 2026. Sanofi's Mixed General Meeting of Shareholders convened on April 29, 2026, under the chairmanship of Frédéric Oudéa. All resolutions were approved with a high level of shareholder support, in particular the appointment of Belén Garijo as a board member. In line with the Board’s decision of February 11, Belén Garijo will assume her duties as Chief Executive Officer on May 1, 2026.","length":410,"tagName":"p"},{"type":"text","content":"Frédéric Oudéa, Chairman of the Board of Directors, stated: “Belén Garijo possesses a rare combination of scientific expertise and operational leadership, developed at the highest level in demanding global environments. A physician by training, she has built a strong track record at the intersection of R&D, strategy, and business model transformation. The Board of Directors has chosen her to lead Sanofi in its next phase of development, with a clear priority: strengthen execution discipline, refine capital allocation, and more consistently translate the quality of our science into sustainable performance. She also has the benefit of many successful years at Sanofi during her career. In an increasingly demanding environment, her approach — grounded in clarity of choices and consistency of implementation — will be essential to accelerate the company's transformation and create long-term value for patients, our shareholders, our employees and all our other stakeholders.”","length":1006,"tagName":"p"},{"type":"text","content":"The General Meeting approved the social and consolidated accounts for fiscal year 2025 a...